Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
TR1 – Major holding by Lanstead
Dec 20, 2023
To view
click here
←
Previous:
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
Next:
TR1 – Major Holding by Lanstead (Date: 28 December 2023)
→
